Viridian Therapeutics Details 2025 Executive Compensation, Board Elections Ahead of Annual Meeting
Summary
Viridian Therapeutics filed its definitive proxy statement for its annual meeting, detailing 2025 executive compensation, including significant bonus payouts and equity awards, alongside proposals for director elections and auditor ratification.
Key Events
-
Annual Meeting Scheduled
The company will hold its 2026 Annual Meeting of Stockholders on June 2, 2026, to vote on director elections, auditor ratification, and executive compensation.
-
Significant 2025 Executive Compensation
Named Executive Officers received 150% of their target annual cash bonuses for 2025, driven by clinical and financing milestones. CEO Stephen Mahoney's "compensation actually paid" for 2025 was $18.8 million.
-
Compensation Not Tied to Financial Performance
The company explicitly stated that executive compensation "actually paid" is not linked to financial performance measures, despite reporting a net loss of $342.6 million in 2025.
-
Related Party Transactions Disclosed
Details were provided on ongoing agreements with Paragon Therapeutics, involving significant payments for R&D and licensing, where Fairmount Funds Management LLC is a major shareholder in both entities.
Analysis
This definitive proxy statement outlines the agenda for Viridian Therapeutics' upcoming annual meeting, including the election of two Class II directors, ratification of KPMG LLP as the independent auditor, and advisory votes on executive compensation and its frequency. The filing provides extensive details on 2025 executive compensation, noting a 150% payout for the annual cash bonus plan due to achieving "stretch" performance criteria related to clinical milestones and financing. CEO Stephen Mahoney's "compensation actually paid" for 2025 was $18.8 million, while the company reported a net loss of $342.6 million. This compensation structure, particularly the high payouts amidst substantial losses and following a recent 26% stock drop (April 6, 2026) due to competitor news, could draw significant shareholder scrutiny. The company previously noted a 78% Say-on-Pay approval in 2025, indicating existing shareholder concerns about executive compensation. The filing also discloses related party transactions with Paragon Therapeutics, where a major shareholder (Fairmount) has significant interests in both entities, involving substantial payments for R&D and licensing. Investors will be watching the shareholder meeting for votes on these proposals and any further commentary on the company's strategy and executive compensation in light of recent market challenges.
At the time of this filing, VRDN was trading at $14.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.76 to $34.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.